US Patent

US7888362 — Piperazine-substituted benzothiophenes for treatment of mental disorders

Composition of Matter · Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2026-04-12 · 0y expired

Vulnerability score 7/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a heterocyclic compound represented by the general formula (1) for treating mental disorders.

USPTO Abstract

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

Drugs covered by this patent

Patent Metadata

Patent number
US7888362
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-04-12
Drug substance claim
Yes
Drug product claim
No
Assignee
Otsuka Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.